

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|---|

<p>The Committee noted a potential equality issue that was raised during the scoping workshop. A workshop attendee suggested that the LUME-Lung 1 trial excluded patients whose disease progressed after maintenance therapy but that some patients now have maintenance therapy after first-line induction therapy. The marketing authorisation wording implies that this group is included 'in combination with docetaxel for adult patients with locally advanced, metastatic or locally recurrent non-small-cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy'. The Committee was aware that people having maintenance therapy are not a 'protected group' according to the equality legislation, and that there was no trial evidence for the effectiveness of nintedanib in this group. Therefore, it concluded that it is unclear whether this group would get a benefit from nintedanib plus docetaxel and the Committee agreed that this did not present an equality issue.</p>
--

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these? |
|--|

No

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No

7. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Yes in section 4.20

Approved by Associate Director (name): Elisabeth George

Date: 15/12/2014

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of Nintedanib for previously treated locally advanced, metastatic or locally recurrent non-small-cell lung cancer

Issue date: July 2015

Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No

5. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes in section 4.21

Approved by Centre or Programme Director (name): Meindert Boysen

Date: 13/03/2015